{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"691"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"715"}],"units":"Participants"}],"description":"Participants were assessed for a shift from a baseline platelet count of \\<75 Gi/L to a count \\>=90 Gi/L during the OL Phase (up to 9 weeks). Local laboratories were used for platelet function tests. Platelet counts were measured by blood draw.","groups":[{"description":"Participants with a platelet count of \\<75 giga (10\\^9) cells per liter (Gi/L) initially received eltrombopag 25 milligrams (mg) once daily (QD) for 2 weeks. After 2 weeks, if the platelet count was \\<90 Gi/L, participants underwent dose escalation to 50 mg QD for 2 weeks. If platelet counts still remained \\<90 Gi/L, further dose escalations to 75 mg QD (up to 2 weeks) and 100 mg QD (up to a maximum of 3 weeks) were allowed. Participants who achieved platelet counts \\>=90 Gi/L during the OL Phase (maximum of up to 9 weeks) were eligible to enter the Double-blind (DB) Antiviral Treatment Phase, whereas those who failed to reach platelet counts \\>=90 Gi/L were discontinued from eltrombopag and had to attend the post-treatment follow-up visits.","id":"OG000","title":"Eltrombopag: OL Phase"}],"paramType":"NUMBER","populationDescription":"Safety Population: all participants who had received study drug in the OL Phase","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 9 in the OL Phase","title":"Number of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 90 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase","type":"SECONDARY","unitOfMeasure":"participants"}